logo

For the Inventor, By the Inventor

Welwyn, United Kingdom

Carey Ernest Smithen

This inventor holds 8 USPTO granted patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 1977-1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carey Ernest Smithen. Retrieved from https://idiyas.com/inventor/carey-ernest-smithen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 51(Granted Patents)


Location History:

  • Welwyn, EN (1977 - 1978)
  • Welwyn, GB (1978)
  • Welwyn Garden City, GB (1980 - 1988)

Company Filing History:

goldMedal8 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 1977-1988

Loading Chart...
8 patents (USPTO):Explore Patents
1. 4774253 - Oxazole and isoxazole derivatives having anti-arthritic activity (1988-09-27),
2. 4241060 - Nitroimidazoles and compositions thereof (1980-12-23),
3. 4105852 - Substituted phenyl ketones (1978-08-08),
4. 4071525 - Substituted phenyl ketones (1978-01-31),
5. 4069229 - Substituted phenyl ketones (1978-01-17),
6. 4046751 - Substituted phenyl ketones (1977-09-06),
7. 4044017 - Substituted phenyl ketones (1977-08-23),
8. 4007219 - Benzophenone glycinamide derivatives (1977-02-08),

Title: Carey Ernest Smithen: Innovator in Pharmaceutical Chemistry

Introduction

Carey Ernest Smithen is a notable inventor based in Welwyn, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with therapeutic applications. With a total of 8 patents to his name, Smithen's work has had a considerable impact on medical science.

Latest Patents

Among his latest patents are innovative compounds such as oxazole and isoxazole derivatives that exhibit anti-arthritic activity. These compounds are characterized by specific structural formulas that allow for various substitutions, enhancing their therapeutic potential. Another notable patent involves nitroimidazoles, which serve as hypoxic-cell radiosensitizers and antiprotozoal agents. These advancements highlight Smithen's commitment to addressing complex medical challenges through innovative chemical solutions.

Career Highlights

Smithen is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work there has allowed him to focus on developing new therapeutic agents that can improve patient outcomes. His extensive research and patent portfolio reflect his dedication to advancing medical science.

Collaborations

Throughout his career, Smithen has collaborated with esteemed colleagues, including Antonin Krohn and Cedric H Hassall. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Carey Ernest Smithen's contributions to pharmaceutical chemistry through his patents and collaborations underscore his role as a key innovator in the field. His work continues to influence the development of new therapeutic agents that can benefit patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…